IP Library Granted Patent US 11,525,003
Granted Patent B2
US 11,525,003 · App. 16/665,359 · Granted Dec 13, 2022

Anti-B7-H3 antibodies and diagnostic uses thereof

Inventors: Fernando Jose Rebelo do Couto (Pleasanton, CA); Zhiming Liao (Livermore, CA); Yifei Zhu (San Jose, CA)
Assignee: Ventana Medical Svstems, Inc.
C07K16/2827G01N33/57407G01N33/57423G01N33/57438G01N33/57492C07K2317/14C07K2317/34C07K2317/51C07K2317/515C07K2317/565C07K2317/92G01N2333/70532
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,525,003
App. No.
16/665,359
Granted
Dec 13, 2022
Kind
B2
Abstract

Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.

Claims (26)

1. A composition comprising a fragment of human B7-H3 from 14 to 50 amino acids in length linked to a carrier protein, wherein the fragment of human B7-H3 comprises SEQ ID NO: 1 and the carrier protein is keyhole limpet haemocyanin (KLH).

2. The composition of claim 1 , wherein the fragment of human B7-H3 is from 14 to 40 amino acids in length.

3. The composition of claim 1 , wherein the fragment of human B7-H3 is from 14 to 30 amino acids in length.

4. The composition of claim 1 , wherein the fragment of human B7-H3 is from 14 to 25 amino acids in length.

5. The composition of claim 1 , wherein the fragment of human B7-H3 is from 14 to 20 amino acids in length.

6. The composition of claim 1 , wherein the fragment of human B7-H3 consists essentially of SEQ ID NO: 1.

7. The composition of claim 1 , wherein the fragment of human B7-H3 consists of SEQ ID NO: 1.

8. An isolated B cell capable of producing an antibody that specifically binds to SEQ ID NO: 1, wherein said isolated B-cell is obtained by a method comprising:

(a) immunizing an animal with a fragment of human B7-H3 from 14 to 50 amino acids in length linked to a carrier protein, wherein the fragment of human B7-H3 comprises SEQ ID NO: 1, wherein the carrier protein is keyhole limpet haemocyanin (KLH), and wherein the animal is a rabbit, rat, mouse, or goat;

(b) isolating antibody-expressing B-cells from the animal; and

(c) screening the antibody-producing B-cells for the presence of a B-cell that produces the antibody that specifically binds to SEQ ID NO: 1.

9. The isolated B cell of claim 8 , wherein the fragment of human B7-H3 is from 14 to 40 amino acids in length.

10. The isolated B cell of claim 8 , wherein the fragment of human B7-H3 is from 14 to 30 amino acids in length.

11. The isolated B cell of claim 8 , wherein the fragment of human B7-H3 is from 14 to 25 amino acids in length.

12. The isolated B cell of claim 8 , wherein the fragment of human B7-H3 is from 14 to 20 amino acids in length.

13. The isolated B cell of claim 8 , wherein the fragment of human B7-H3 consists essentially or consists of SEQ ID NO: 1.

14. A hybridoma capable of producing an antibody that specifically binds to SEQ ID NO: 1, wherein the hybridoma is obtained by a method comprising:

(a) immunizing an animal with a fragment of human B7-H3 from 14 to 50 amino acids in length linked to a carrier protein, wherein the fragment of human B7-H3 comprises SEQ ID NO: 1, wherein the carrier protein is keyhole limpet haemocyanin (KLH), and wherein the animal is a rabbit, rat, mouse, or goat;

(b) isolating antibody-producing B-cells from the animal;

(c) screening the antibody-producing B-cells for the presence of a B-cell that produces an antibody that specifically binds to SEQ ID NO: 1; and

(d) preparing the hybridoma from the B-cell that produces the antibody that specifically binds to SEQ ID NO: 1.

15. The hybridoma of claim 14 , wherein the fragment of human B7-H3 is from 14 to 40 amino acids in length.

16. The hybridoma of claim 14 , wherein the fragment of human B7-H3 is from 14 to 30 amino acids in length.

17. The hybridoma of claim 14 , wherein the fragment of human B7-H3 is from 14 to 25 amino acids in length.

18. The hybridoma of claim 14 , wherein the fragment of human B7-H3 is from 14 to 20 amino acids in length.

19. The hybridoma of claim 14 , wherein the fragment of human B7-H3 consists essentially of or consists of SEQ ID NO: 1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: SPRING BIOSCIENCE CORPORATION
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 052932/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: COUTO, FERNANDO JOSE REBELO DO; LIAO, ZHIMING; ZHU, YIFEI
To: SPRING BIOSCIENCE CORPORATION
Reel/Frame 050847/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: COUTO, FERNANDO JOSE REBELO DO; LIAO, ZHIMING; ZHU, YIFEI
To: SPRING BIOSCIENCE CORPORATION
Reel/Frame 050847/0104 →
Continuity (5)
Division 15363992 · Nov 29, 2016
Continuation PCTEP2015061777 · May 28, 2015
Provisional Application 62082681 · Nov 21, 2014
Provisional Application 62004605 · May 29, 2014
Related Publication 20200048353A1 · Feb 13, 2020